CoQ10 vs MitoQ
Two mitochondria-targeted antioxidants with the same pitch and very different trial records — one has a positive heart-failure mortality trial, the other one positive vascular RCT and several recent nulls.
CoQ10
Coenzyme Q10, ubiquinone, ubiquinol
Q-SYMBIO showed a real reduction in cardiovascular mortality and hospitalization when added to standard heart-failure therapy — a hard outcome, not a surrogate. Migraine prevention data are real but more modest; statin-myopathy relief did not beat placebo in meta-analysis. The 'declines with age, so restore it' pitch aimed at healthy adults has no supporting outcome trial.
Full CoQ10 evidence reviewMitoQ
Mitoquinone mesylate
One real human RCT reversed vascular endothelial aging markers in healthy older adults, but the Parkinson's trial was a clean negative, and kidney-safety and exercise-redox RCTs since have also come back null — the vascular signal hasn't been shown to generalize beyond that one outcome.
Full MitoQ evidence reviewSide by side
| CoQ10 | MitoQ | |
|---|---|---|
| Marketed for | Heart failure adjunct, statin-myopathy relief, migraine prevention, general anti-aging 'energy' | Mitochondrial antioxidant support, vascular aging, general anti-aging |
| Evidence grade | Clinical data | Clinical data |
| Family | NAD⁺ & mitochondrial | NAD⁺ & mitochondrial |
| Key human source | Q-SYMBIO, JACC Heart Failure 2014 | Rossman 2018 vascular RCT, Hypertension |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
CoQ10's Q-SYMBIO trial showed a real reduction in cardiovascular mortality and hospitalization in heart-failure patients — a hard outcome. MitoQ's best human result is a six-week vascular-function RCT in healthy older adults, promising but narrower, and its more recent kidney-safety and exercise-redox trials have come back null. Neither has been compared directly, and neither has outcome data supporting the general 'anti-aging energy' pitch both are sold on.
CoQ10 fits if
You have (or are managing) heart failure and want the antioxidant with an actual mortality-outcome trial behind it, discussed with your cardiologist.
MitoQ fits if
You're interested in the mitochondria-targeted-antioxidant mechanism specifically and want the one with a positive human vascular-aging RCT, understanding the evidence outside that trial is thin.